Cited 0 times in
근치적 위절제술을 시행받은 위암 환자에서 상황(메시마-엑스)의 항종양 효과
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김주항 | - |
dc.contributor.author | 노성훈 | - |
dc.contributor.author | 노재경 | - |
dc.date.accessioned | 2020-07-03T17:41:59Z | - |
dc.date.available | 2020-07-03T17:41:59Z | - |
dc.date.issued | 1997 | - |
dc.identifier.issn | 0496-6872 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/177768 | - |
dc.description.abstract | PURPOSE: The Mesima-Ex is a kind of biologic response modifier, which is extracted from a mushroom called Phellinus linteus. Mesima-Ex consists of various chemical compounds which include protein bound polysaccharide, mucoprotein, triterpenoid, and quinones. Mesima-Ex exerts its antitumor effects by augmenting host immune response without any toxic side effects. In vitro study, Mesima-Ex seems to potentiates antibody dependent cell mediated cytotoxicity (ADCC) and cell mediated cytotoxicity (CMI) against tumor cells. We initiated this study to verify antitumor effects of Mesima-Ex as an antineoplastic agent. MATERIALS AND METHOD: Gastric cancer patients who underwent curative resection with normal hepatic and renal function were eligible. They were divided into two groups by random number table. One group (N=30: Mesima-Ex group) received postoperative adjuvant chemotherapy with 5-FU (500 mg/m2 weekly), adriamycin (40 mg/m2 every 3 weeks) and Mesima-Ex (6 cap daily per Os). Another group (N=37: control group) received 5-FU and adriamycin only without Mesima-Ex. NK (natural killer cell) activity, ADCC (antibody dependent cell mediated cytotoxicity), CD4 , and CD8 cells were measured and an analysis of disease free survival rate of the two study groups was performed. RESULTS: Sixty seven patients were enrolled in this study. Their median age was 55 years old. NK activity (basal activity: 25%) was enhanced significantly at the 2nd, and 4th months in the Mesima-Ex group (28.9%, 43.4%, p<0.05). ADCC was also enhanced from 37% to 42.1% at the 2nd month in the Mesima-Ex group (p<0.05). The control group did not show any significant change in NK activity or ADCC. The CD4 cell ratio was increased from 37% to 42.1% at the 2nd months in the Mesima-Ex group but not in the control group (p<0.05). There was no significant change in CD8 subsets (p>0.05). There were no toxic side effects more than grade III from Mesima-Ex administration. The two year disease free survival rate was higher in the Mesima-Ex group than that of the control group (77% vs 58%, p<0.05). CONCLUSION: Mesima-Ex can be used safely as an immunomodulator with standard chemotherapeutic agents for purpose of adjuvant chemotherapy. Mesima-Ex was effective in augmenting host immune response in vitro. The Mesima-Ex group showed a higher two year disease free survival rate than that of the control group. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | Korean | - |
dc.publisher | 대한암학회 | - |
dc.relation.isPartOf | Journal of the Korean Cancer Association (대한암학회지) | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | 근치적 위절제술을 시행받은 위암 환자에서 상황(메시마-엑스)의 항종양 효과 | - |
dc.title.alternative | The Effects of Mesima-Ex, the Immunomodulator in Curatively Resected Gastric Cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | 조세행 | - |
dc.contributor.googleauthor | 김주항 | - |
dc.contributor.googleauthor | 박병규 | - |
dc.contributor.googleauthor | 박수진 | - |
dc.contributor.googleauthor | 안상훈 | - |
dc.contributor.googleauthor | 정현철 | - |
dc.contributor.googleauthor | 노재경 | - |
dc.contributor.googleauthor | 김병수 | - |
dc.contributor.googleauthor | 노성훈 | - |
dc.contributor.localId | A00945 | - |
dc.contributor.localId | A01281 | - |
dc.contributor.localId | A01290 | - |
dc.relation.journalcode | J01813 | - |
dc.subject.keyword | Mesima-Ex | - |
dc.subject.keyword | Immunomodulator | - |
dc.subject.keyword | Phellinus linteus | - |
dc.subject.keyword | Gastric cancer | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | 김주항 | - |
dc.contributor.affiliatedAuthor | 노성훈 | - |
dc.contributor.affiliatedAuthor | 노재경 | - |
dc.citation.volume | 29 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 800 | - |
dc.citation.endPage | 806 | - |
dc.identifier.bibliographicCitation | Journal of the Korean Cancer Association (대한암학회지), Vol.29(5) : 800-806, 1997 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.